PMVP PMV Pharmaceuticals, Inc.: institutional ownership and insider trading
66 funds reported holding $49.1M of PMV Pharmaceuticals, Inc. in their latest 13F filings; in Q2 2026 funds net sold $3.41M, with 4 new positions and 9 funds selling out; over the last 12 months insiders bought $0 and sold $0 on the open market.
PMVP revenue and earnings
- Quarter ended Jun 30, 2026: revenue n/a, net income −$18.1M, EPS -0.34
- Quarter ended Mar 31, 2026: revenue n/a, net income −$18.0M, EPS -0.34
- Quarter ended Dec 31, 2025: revenue n/a, net income −$18.0M, EPS -0.33
- Quarter ended Sep 30, 2025: revenue n/a, net income −$21.1M, EPS -0.40
Famous investors holding PMVP
- Two Sigma (Two Sigma Investments): $2.62M, 0.0% of the portfolio
- Ken Griffin (Citadel Advisors): $334K, 0.0% of the portfolio
Largest institutional holders of PMVP
- BML Capital Management, LLC — $7.14M
- TANG CAPITAL MANAGEMENT LLC — $5.69M
- Sio Capital Management, LLC — $3.53M
- Euclidean Capital LLC — $3.52M
- ADAGE CAPITAL PARTNERS GP, L.L.C. — $3.16M
- ACADIAN ASSET MANAGEMENT LLC — $2.97M
- VANGUARD GROUP INC — $2.71M
- VANGUARD CAPITAL MANAGEMENT LLC — $2.70M
- ArrowMark Colorado Holdings LLC — $2.63M
- TWO SIGMA INVESTMENTS, LP — $2.62M
Recent PMVP insider trades
- Oct 23, 2025: Orbimed Advisors Llc sold 1,000,000 shares ($1.52M)
- Sep 10, 2025: Orbimed Advisors Llc sold 500,000 shares ($900K)
- Jul 1, 2025: Jalota Deepika sold 33,065 shares ($35.0K)
- Jul 1, 2025: Carulli Michael sold 28,249 shares ($29.9K)
5%+ owners
- Srinivas Akkaraju: 9.9% (Schedule 13G, filed Sep 15, 2026)